Literature DB >> 3243379

Effectiveness of enteric-coated preparations on nutritional parameters in cystic fibrosis. A long-term study.

A Carroccio1, F Pardo, G Montalto, L Japichino, G Iacono, M Collura, A Notarbartolo.   

Abstract

To evaluate the effectiveness of enteric-coated pancreatic enzyme supplements in comparison to conventional preparations of ingested enzyme on growth and nutritional parameters of patients with cystic fibrosis, we conducted a long-term study involving 40 patients. The data reproduced here were recorded after 6 months of therapy with powder-containing capsules or with enteric-coated products. Fat absorption was estimated by measurement of steatorrhoea with the steatocrit method. All parameters studied improved after enteric-coated pancreatic enzyme therapy, with a statistically significant increase in weight, cholesterol and haemoglobin values. Furthermore, the number of patients with positive steatocrit test was lower after therapy with enteric-coated enzyme supplementation. These findings suggest that the enteric-coated product not only reduces steatorrhoea, but above all improves the nutritional parameters and growth of patients affected by cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3243379     DOI: 10.1159/000199788

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  4 in total

1.  Growth Deficiency in Cystic Fibrosis Is Observable at Birth and Predictive of Early Pulmonary Function.

Authors:  Rebecca Darrah; Rebecca Nelson; Elizabeth G Damato; Michael Decker; Anne Matthews; Craig A Hodges
Journal:  Biol Res Nurs       Date:  2016-04-13       Impact factor: 2.522

2.  Prevalence of diabetes mellitus and impaired glucose tolerance in cystic fibrosis.

Authors:  A Carroccio; L Iapichino; G Montalto; F Pardo; G Iacono; M Soresi; M Collura; A Notarbartolo
Journal:  Acta Diabetol Lat       Date:  1990 Oct-Dec

3.  Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis.

Authors:  Zhumin Zhang; Mary J Lindstrom; HuiChuan J Lai
Journal:  J Pediatr       Date:  2013-03-25       Impact factor: 4.406

4.  Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy. A long-term study in cystic fibrosis.

Authors:  A Carroccio; F Pardo; G Montalto; L Iapichino; M Soresi; M R Averna; G Iacono; A Notarbartolo
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.